The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
The Receptor-associated Protein (RAP) As A Molecular Chaperone For The Amyloid Protein (Abeta) Of Alzheimers Disease
Funder
National Health and Medical Research Council
Funding Amount
$402,403.00
Summary
Our research will examine the role of a protein known as the receptor-associated protein (RAP) in Alzheimer's disease. We will determine whether the protein contributes to the progression of Alzheimer's disease and we will examine the possiblity that that RAP may be used as a drug to treat the disease. The project could potentially have direct benefit for patients by leading to an effective treatment for dementia associated with Alzheimer's disease.
Regulation Of The Beta-secretase (BACE1) By Glycosaminoglycans
Funder
National Health and Medical Research Council
Funding Amount
$561,212.00
Summary
Alzheimer's disease is the leading cause of dementia in the elderly. Because of the prolonged institutionalisation of patients, it is a major health care burden. This project aims to develop novel drugs which can treat Alzheimer's disease by inhibiting production of the protein which causes the neurodegeneration.
PATHOGENESIS OF ALZHEIMERS DISEASE AND RELATED DISORDERS: MECHANISM OF TAU PATHOLOGY
Funder
National Health and Medical Research Council
Funding Amount
$295,983.00
Summary
A protein called tau has an essential role in the pathogenesis of Alzheimer's disease (AD), frontotemporal dementia (FTD) and related dementias. We have developed novel transgenic models, which allow us to treat the mice and to abrogate the clinical symptoms. As we have dissected the underlying molecular mechanisms, our ultimate goal is to develop a treatment approach based on these mechanisms and thereby reduce the socio-economic burden of these debilitating diseases.
Extracellular Matrix, Cell-surface Receptors And Alzheimer's Disease: A Novel Glycoform Of Acetylcholinesterase
Funder
National Health and Medical Research Council
Funding Amount
$265,074.00
Summary
Alzheimer's disease is the leading cause of dementia in the elderly, affecting approximately 5-10% of the population over the age of 65. With an increasingly ageing population, Alzheimer's disease will be a major health problem in the next century unless effective treatments (probably in combination with early diagnosis) are found. We have identified a novel form of a protein acetylcholinesterase (AChE-AD), which is present in high levels in the brains of patients with Alzheimer's disease. Our w ....Alzheimer's disease is the leading cause of dementia in the elderly, affecting approximately 5-10% of the population over the age of 65. With an increasingly ageing population, Alzheimer's disease will be a major health problem in the next century unless effective treatments (probably in combination with early diagnosis) are found. We have identified a novel form of a protein acetylcholinesterase (AChE-AD), which is present in high levels in the brains of patients with Alzheimer's disease. Our work has shown that the accumulation of another protein in the brains of Alzheimer patients, known as the amyloid protein, is the cause of the increase in AChE-AD. This finding is important for two reasons: 1) Identification of the mechanism by which the amyloid protein causes an increase in AChE-AD will tell us about some of the basic causes of Alzheimer's disease. 2) AChE-AD may be a useful diagnostic marker of Alzheimer's disease. At present, diagnosis is performed by clinical examination. This is a time consuming and inaccurate process. A biochemical diagnostic marker will provide an objective criterion with which to diagnose Alzheimer's disease. Therefore, our research is aimed at: Aim 1: Evaluating AChE-AD as a diagnostic marker. Aim 2: Developing tools with which we can more easily measure AChE-AD. Aim 3: Understanding the basic biochemical mechanisms which cause the increase in AChE-AD in the brains of patients. Aim 4: Examining whether AChE-AD may contribute to the cause of Alzheimer's disease.Read moreRead less
Lipid Rafts, Amyloid Neurotoxicity And Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$318,267.00
Summary
Alzheimer's disease is the major cause of dementia in the elderly. Individuals with Alzheimer's disease exhibit a slow decline in cognition which usually results in prolonged institutionalisation. This creates an enormous burden on society. The project aims to identify mechanisms which cause Alzheimer's disease. Specifically, it will examine how a component of the brain, known as the amyloid protein, contributes to nerve cell degeneration. It is hoped that by identifying these mechanisms, new ta ....Alzheimer's disease is the major cause of dementia in the elderly. Individuals with Alzheimer's disease exhibit a slow decline in cognition which usually results in prolonged institutionalisation. This creates an enormous burden on society. The project aims to identify mechanisms which cause Alzheimer's disease. Specifically, it will examine how a component of the brain, known as the amyloid protein, contributes to nerve cell degeneration. It is hoped that by identifying these mechanisms, new targets for drug development will be found.Read moreRead less
Cholinergic Abnormalities In Alzheimer's Disease: Identification Of Novel Therapeutic Targets
Funder
National Health and Medical Research Council
Funding Amount
$478,500.00
Summary
The aim of this project is to develop new drugs for the treatment of Alzheimer's disease. Alzheimer's disease is a disease of ageing commonly associated with memory loss. The disease is caused by the build up of amyloid protein in the brain. However, it is not known how amyloid protein causes degeneration of normal brain function. Our previous studies have shown that amyloid protein targets two components which are important for normal brain function. These components are 1) acetylcholinesterase ....The aim of this project is to develop new drugs for the treatment of Alzheimer's disease. Alzheimer's disease is a disease of ageing commonly associated with memory loss. The disease is caused by the build up of amyloid protein in the brain. However, it is not known how amyloid protein causes degeneration of normal brain function. Our previous studies have shown that amyloid protein targets two components which are important for normal brain function. These components are 1) acetylcholinesterase and 2) nicotinic receptors, which are known to be important for memory. The aim of this application is to identify the mechanisms by which amyloid protein targets acetylcholinesterase and nicotinic receptors and to design inhibitors of this interaction which may ultimately provide a platform for future drug development.Read moreRead less
The Translocator Protein (TSPO) As A Novel Target For The Treatment Of Alzheimers Disease
Funder
National Health and Medical Research Council
Funding Amount
$629,260.00
Summary
Alzheimer's disease (AD) is the most prevalent dementia, characterized by progressive loss of memory. An estimated 230,000 Australians currently suffer from AD, causing a huge impact on their families and carers, as well as on national finances. The present therapies are very limited, and there is no cure. Thus, there is a need for novel treatment strategies. We have developed novel drugs that represent an innovative approach to the treatment of AD.